Full Press Release Details
AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer
patent provides protection for BF-223 and related compounds
MD - Date - BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"),
a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development
of pharmaceuticals and biologics, today announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company's
novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This follows the July 2023 announcement
of the issuance of U.S. Patent No. 11,712,435 for this invention (link), with issuance of patents expected in additional territories
patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, thereby addressing a key difficulty
associated with the potential use of mebendazole for oncology indications, and include BF-223, a key asset in the Company's pipeline
of in-licensed drugs. The Company previously announced positive results from a preclinical study demonstrating that BF-223 has anticancer
activity in an animal model for glioblastoma (link).
patent grant further strengthens intellectual property protection of this key asset in our pipeline," said Vin Singh, founder and
CEO of BullFrog AI. "Mebendazole has shown promise in treating various types of cancer, and the results of our preclinical study
evaluating BF-223 in an animal model of glioblastoma support our thesis that prodrugs of mebendazole may provide enhanced therapeutic
potential, thereby improving the likelihood of clinical success. We look forward to working with strategic partners to monetize this
promising asset for the treatment of glioblastoma and other oncology indications."
AI is a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals
and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development
using its proprietary bfLEAP artificial intelligence platform to create and analyze networks of biological, clinical, and real-world
data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP for use at several critical
stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development
costs by decreasing failure rates for new therapeutics.
more information visit BullFrog AI at:
press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about
future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events
or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business
prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those
that use terminology such as "may," "should," "expects," "anticipates," "contemplates,"
"estimates," "believes," "plans," "projected," "predicts," "potential,"
or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider
various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially
from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press
release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ
materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking
statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other
statements made from time to time by us or our representatives might not occur.
BullFrog AI Holdings, Inc.